Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years. / Rieckmann, Andreas; Meyle, Kathrine Damm; Rod, Naja Hulvej; Baker, Jennifer Lyn; Benn, Christine Stabell; Aaby, Peter; Sørup, Signe.

In: Vaccine, Vol. 37, No. 44, 2019, p. 6730-6736.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Rieckmann, A, Meyle, KD, Rod, NH, Baker, JL, Benn, CS, Aaby, P & Sørup, S 2019, 'Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years', Vaccine, vol. 37, no. 44, pp. 6730-6736. https://doi.org/10.1016/j.vaccine.2019.09.023

APA

Rieckmann, A., Meyle, K. D., Rod, N. H., Baker, J. L., Benn, C. S., Aaby, P., & Sørup, S. (2019). Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years. Vaccine, 37(44), 6730-6736. https://doi.org/10.1016/j.vaccine.2019.09.023

Vancouver

Rieckmann A, Meyle KD, Rod NH, Baker JL, Benn CS, Aaby P et al. Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years. Vaccine. 2019;37(44):6730-6736. https://doi.org/10.1016/j.vaccine.2019.09.023

Author

Rieckmann, Andreas ; Meyle, Kathrine Damm ; Rod, Naja Hulvej ; Baker, Jennifer Lyn ; Benn, Christine Stabell ; Aaby, Peter ; Sørup, Signe. / Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years. In: Vaccine. 2019 ; Vol. 37, No. 44. pp. 6730-6736.

Bibtex

@article{da9eedb04b0e4514a94ddc640bb0a10b,
title = "Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years",
abstract = "BACKGROUND: Early smallpox and Bacillus Calmette-Gu{\'e}rin (BCG) vaccinations have been associated with reduced risk of cutaneous malignant melanoma (CMM). We assessed the association between pre-school smallpox vaccination and early-school BCG vaccination and CMM in a young Danish population.METHODS: We conducted a register-based case-cohort study of individuals growing up during the phase-out period of smallpox and BCG vaccination in Denmark (born 1965-1976) utilising the decrease in vaccination during this period. Information on childhood vaccinations and potential confounders from Copenhagen school health records were linked with nationwide registers on cancer (CMM diagnoses), migrations and deaths by personal identification numbers.RESULTS: The individuals were followed from age 18 until 31/12/2014 (maximum age at end of follow-up, 49 years). 188 cases of CMM occurred in the background population of 46,239 individuals; 172 CMM cases (91%) had full information and were analysed. The adjusted hazard ratio (HR) for CMM by BCG and/or smallpox vaccination compared with neither vaccine was 1.29 (95% confidence interval (CI) 0.72-2.31). For smallpox vaccination only, HR = 1.23 (95% CI 0.53-2.86) for BCG vaccination only, HR = 1.13 (95% CI 0.61-2.09) and for both smallpox and BCG vaccination, HR = 1.75 (95% CI 0.87-3.48) compared with none of these. Vaccination below the age of one year gave similar results.CONCLUSIONS: We found no strong beneficial effect of smallpox and BCG vaccination against CMM among young adult Danes and with broad confidence intervals our data alone could be compatible with both modest preventive effects, no effects, and modest harmful effects. Our estimates do not contradict a potential modest beneficial effect of neonatal vaccination.",
author = "Andreas Rieckmann and Meyle, {Kathrine Damm} and Rod, {Naja Hulvej} and Baker, {Jennifer Lyn} and Benn, {Christine Stabell} and Peter Aaby and Signe S{\o}rup",
note = "Copyright {\textcopyright} 2019 Elsevier Ltd. All rights reserved.",
year = "2019",
doi = "10.1016/j.vaccine.2019.09.023",
language = "English",
volume = "37",
pages = "6730--6736",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "44",

}

RIS

TY - JOUR

T1 - Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years

AU - Rieckmann, Andreas

AU - Meyle, Kathrine Damm

AU - Rod, Naja Hulvej

AU - Baker, Jennifer Lyn

AU - Benn, Christine Stabell

AU - Aaby, Peter

AU - Sørup, Signe

N1 - Copyright © 2019 Elsevier Ltd. All rights reserved.

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Early smallpox and Bacillus Calmette-Guérin (BCG) vaccinations have been associated with reduced risk of cutaneous malignant melanoma (CMM). We assessed the association between pre-school smallpox vaccination and early-school BCG vaccination and CMM in a young Danish population.METHODS: We conducted a register-based case-cohort study of individuals growing up during the phase-out period of smallpox and BCG vaccination in Denmark (born 1965-1976) utilising the decrease in vaccination during this period. Information on childhood vaccinations and potential confounders from Copenhagen school health records were linked with nationwide registers on cancer (CMM diagnoses), migrations and deaths by personal identification numbers.RESULTS: The individuals were followed from age 18 until 31/12/2014 (maximum age at end of follow-up, 49 years). 188 cases of CMM occurred in the background population of 46,239 individuals; 172 CMM cases (91%) had full information and were analysed. The adjusted hazard ratio (HR) for CMM by BCG and/or smallpox vaccination compared with neither vaccine was 1.29 (95% confidence interval (CI) 0.72-2.31). For smallpox vaccination only, HR = 1.23 (95% CI 0.53-2.86) for BCG vaccination only, HR = 1.13 (95% CI 0.61-2.09) and for both smallpox and BCG vaccination, HR = 1.75 (95% CI 0.87-3.48) compared with none of these. Vaccination below the age of one year gave similar results.CONCLUSIONS: We found no strong beneficial effect of smallpox and BCG vaccination against CMM among young adult Danes and with broad confidence intervals our data alone could be compatible with both modest preventive effects, no effects, and modest harmful effects. Our estimates do not contradict a potential modest beneficial effect of neonatal vaccination.

AB - BACKGROUND: Early smallpox and Bacillus Calmette-Guérin (BCG) vaccinations have been associated with reduced risk of cutaneous malignant melanoma (CMM). We assessed the association between pre-school smallpox vaccination and early-school BCG vaccination and CMM in a young Danish population.METHODS: We conducted a register-based case-cohort study of individuals growing up during the phase-out period of smallpox and BCG vaccination in Denmark (born 1965-1976) utilising the decrease in vaccination during this period. Information on childhood vaccinations and potential confounders from Copenhagen school health records were linked with nationwide registers on cancer (CMM diagnoses), migrations and deaths by personal identification numbers.RESULTS: The individuals were followed from age 18 until 31/12/2014 (maximum age at end of follow-up, 49 years). 188 cases of CMM occurred in the background population of 46,239 individuals; 172 CMM cases (91%) had full information and were analysed. The adjusted hazard ratio (HR) for CMM by BCG and/or smallpox vaccination compared with neither vaccine was 1.29 (95% confidence interval (CI) 0.72-2.31). For smallpox vaccination only, HR = 1.23 (95% CI 0.53-2.86) for BCG vaccination only, HR = 1.13 (95% CI 0.61-2.09) and for both smallpox and BCG vaccination, HR = 1.75 (95% CI 0.87-3.48) compared with none of these. Vaccination below the age of one year gave similar results.CONCLUSIONS: We found no strong beneficial effect of smallpox and BCG vaccination against CMM among young adult Danes and with broad confidence intervals our data alone could be compatible with both modest preventive effects, no effects, and modest harmful effects. Our estimates do not contradict a potential modest beneficial effect of neonatal vaccination.

U2 - 10.1016/j.vaccine.2019.09.023

DO - 10.1016/j.vaccine.2019.09.023

M3 - Journal article

C2 - 31537447

VL - 37

SP - 6730

EP - 6736

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 44

ER -

ID: 228360693